Debiopharm News Feed

Debiopharm and Vifor Pharma sign an exclusive agreement for the distribution and commercialization of Pamorelin® LA in Switzerland - A drug treatment for prostate cancer and endometriosis

Mon, 14 May 2012 23:00:00 GMT

Lausanne and Villars-sur-Glâne, Switzerland, 15 May 2012 - Debiopharm Group™ (Debiopharm) and Vifor Pharma announce the signing of an exclusive agreement covering the distribution and commercialization in Switzerland of the 1-, 3- and 6-month formulations of Pamorelin® LA and of the 3-month formulation of Salvacyl®. The agreement came into effect on 9 May 2012. Pamorelin® LA, which contains the active substance triptorelin in the form of pamoate salt, is indicated in the treatment of advanced hormone-dependent prostate cancer, endometriosis and female infertility. Salvacyl® is indicated in the treatment of severe sexual deviation in men. The 1- and 3-month formulations of Pamorelin® LA are available immediately, while the introduction of the 6-month formulation of Pamorelin® LA and Salvacyl® will be communicated by Vifor Pharma at a later date.

Developed by Debiopharm, the products Pamorelin® LA and Salvacyl® are manufactured by Debio R.P. in Martigny, Debiopharm's site for applied research, controlled release formulation

A Phase I-II evaluation of the safety and efficacy of the oral HSP90 inhibitor Debio 0932 in combination with Standard of Care in first- and second-line therapy of Stage IIIb or IV NSCLC – The HALO study (HSP90 ...

Mon, 16 Apr 2012 23:00:00 GMT

Van Ingen H (1), Purcea D (1), Brienza S (1), Paz-Ares L (2)

Poster presented at 3rd European Lung Cancer Conference (elcc) in Geneva, Switzerland

(1) Debiopharm SA, Lausanne, Switzerland

(2) Hospital Universitario Virgen del Rocio, Seville, Spain

Debiopharm and Curis Announce Initiation of Phase Ib Expansion Study of HSP90 Inhibitor Debio 0932

Thu, 16 Feb 2012 10:13:48 GMT

Lausanne, Switzerland and Lexington, Mass., USA, February 16, 2012 -- Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop proprietary targeted medicines for cancer treatment, and Debiopharm Group (Debiopharm), a group of companies with a focus on the development of prescription drugs that target unmet medical needs, today announced that Debiopharm has begun treating patients in a Phase Ib clinical trial of Heat Shock Protein 90 (HSP90) inhibitor Debio 0932. Debiopharm recently successfully completed a Phase Ia dose escalation study with Debio 0932 and has indicated that it expects to initiate a combination Phase I/II study in non-small cell lung cancer patients in the second quarter of 2012.

“Our team has been very pleased with the development of Debio 0932, which has become an important molecule in Debiopharm’s pipeline,” said Rolland-Yves Mauvernay, President and Founder of Debiopharm Group. “We believe that HSP90 represents an important molecular target in cancer

Augurix Diagnostics receives the 2011 ‘Debiopharm /Valais Award’ For its point-of-care diagnostic test for the early detection of Celiac disease

Wed, 09 Nov 2011 09:00:56 GMT

Lausanne, Switzerland – November 9, 2011 Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group with a focus on drug development and companion diagnostics, presents the 2011 ‘Debiopharm /Valais Award’ to Augurix Diagnostics (Augurix), a privately held company based in Monthey (Valais), that focuses on point-of-care testing in the field of gastro-enterology and initially on Celiac disease. Debio R.P., the Martigny-based structure of Debiopharm, will award 20’000 Swiss francs to Augurix CEO Thierry Duvanel during the ceremony that will take place on November 10th during the Ark Innovation Day at BioArk.

Augurix has developed a diagnostic test (Simtomax®) used for the screening of Celiac disease. The test replicates existing expensive laboratory diagnostic procedures, using a fraction of the blood sample normally required, and it delivers results in 10 minutes with equivalent reliability. The intended use of Simtomax® is to exclude Celiac disease when performing large screening or differential diagnosis, thereby moving

The Japanese Cancer Association and Debiopharm Group™ present Doctors Arakawa and Kurokawa with the 2011 ‘JCA-Mauvernay Award’for their innovative and outstanding research in the field of cancer

Wed, 05 Oct 2011 07:20:35 GMT

Lausanne, Switzerland – October 5, 2011 Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group with a focus on drug development and companion diagnostics, today presented the ‘JCA-Mauvernay Award’ to Doctor Hirofumi Arakawa from the National Cancer Center Research Institute in Tokyo, for his basic research on the ‘identification and characterisation of p53 target genes’ and to Doctor Mineo Kurokawa from the University of Tokyo, for his applied research on ‘the molecular pathogenesis and therapeutic targets of hematological malignancies’. The ceremony was held during the 70th Annual Meeting of the Japanese Cancer Association (JCA) in Nagoya, Japan. This year the theme was ‘Forward Strides for Cancer Research – Grounds for a Confident Future’. Professor Tetsuo Noda, President of the JCA and Dr Rolland-Yves Mauvernay, Founder and President of Debiopharm Group™ presented both scientists with the 2011 Award for their outstanding and innovative research.

Dr Hirofumi Arakawa works in the division of

Debiopharm Group™ presents the ‘Debiopharm Group™ Life Sciences Award 2011’ and two ‘Junior Debiopharm Group™ Awards 2011’ at the ISREC 2011 Life Sciences Symposium

Thu, 08 Sep 2011 07:35:54 GMT

Lausanne, Switzerland – September 8, 2011 - Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group with a focus on drug development and companion diagnostics, will present tomorrow the ‘Debiopharm Group Life Sciences Award 2011’ to Professor Stefano Piccolo as well as two inaugural ‘Junior Debiopharm Group Life Sciences Awards 2011’ to Professor Etienne Meylan and Doctor Volker Busskamp. The award ceremony will take place at the EPFL (Ecole polytechnique fédérale de Lausanne) during the ISREC (Swiss Institute for Experimental Cancer Research) 2011 Life Sciences Symposium entitled ‘Hallmarks and horizons of cancer’.

The ‘Debiopharm Group Life Sciences Award 2011’ is granted to Professor Stefano Piccolo from the University of Padua, Italy. He has made extensive contributions to the field of cancer, in particular in dissecting the role of a protein secreted by cells called “transforming growth factor beta (TGFb)”, and the relation of TGFb to intracellular signalling pathways involved in cancer initiation

Debiopharm and Ascenta Therapeutics, Inc. announce an exclusive license agreement for the development and commercialization of the IAP (Inhibitor of Apoptosis Protein) Inhibitor AT-406 (called Debio 1143 by Debiopharm) ...

Wed, 07 Sep 2011 08:01:06 GMT

Lausanne, Switzerland, and Malvern, PA, USA, September 7, 2011 Debiopharm Group™ (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, and Ascenta Therapeutics, Inc. (Ascenta), a privately-held, biopharmaceutical company dedicated to the discovery and development of new medicines to treat cancer, have entered into an exclusive worldwide license agreement concerning the development and commercialization of AT-406 (called Debio 1143 by Debiopharm) a small molecule IAP inhibitor currently in phase I development. By targeting inhibitors of apoptosis proteins, AT-406 (or Debio 1143) can induce cancer cell death and/or potentiate the efficacy of other treatments and is expected to be effective in the treatment of various cancers in combination with anti-cancer therapies.

“We are very excited about this collaboration with Ascenta Therapeutics. This company has an impressive scientific team and expertise in the field of apoptosis”, said Dr Rolland-Yves Mauvernay, president and founder of Debiopharm S.A.,

Debiopharm Group™ s’installe dans son "Espace «après-demain»" au sein du quartier de l’innovation de l’EPFL

Thu, 01 Sep 2011 07:21:54 GMT

Lausanne, le 1er septembre 2011 – Debiopharm Group™ (Debiopharm), un groupe biopharmaceutique global, basé en Suisse, qui se concentre sur le développement de thérapies innovantes, annonce l’ouverture de son nouveau laboratoire, appelé "Espace « après-demain » au cœur du campus de l’EPFL (Ecole polytechnique fédérale de Lausanne), dans le bâtiment G du quartier de l’innovation. Ces nouveaux locaux, d’une surface 400m2, accueilleront une équipe de quinze personnes regroupant des experts galéniques, analytiques et de biologie moléculaire. La mission principale de ce groupe se résume en trois mots « innovative pharmaceutical development ». Le laboratoire apportera ainsi un soutien actif dans la sélection et le développement pharmaceutique des ‘Development Candidates’. Le laboratoire bénéficiera de la grande expertise de ses membres non seulement dans la caractérisation physico-chimique et biopharmaceutique, mais aussi dans le développement d’approches innovantes. Ce nouveau site permettra de renforcer les échanges importants déjà existants entre Debiopharm et

INC Research and Debiopharm Group ™ announce Strategic Partnership

Tue, 26 Jul 2011 00:00:00 GMT

Lausanne (Switzerland) and Raleigh, NC, July 26, 2011 INC Research, LLC, a therapeutically focused contract research organisation (CRO) with a trusted process for delivering reliable results, and Debiopharm Group™ (“Debiopharm”), a Swiss-based global biopharmaceutical group with a focus on drug development and companion diagnostics, today announced a strategic partnership. Under the terms of the agreement, Debiopharm will entrust INC Research with the management of a clinical study linked to an important project in Debiopharm’s pipeline. Both parties have furthermore agreed on a framework partnership pertaining to future clinical studies to be conducted by INC Research for Debiopharm.

“Debiopharm’s reputation and success in establishing partnerships is aligned very closely with our vision of creating strategic relationships that improve the speed, efficiency, and quality of drug development,” said Kelvin Logan, Ph.D., president INC Research Europe and Asia Pacific, who added “we are pleased to offer our therapeutic expertise along with our experience

Continuity as Debiopharm Group™ management moves forward

Thu, 14 Jul 2011 08:02:29 GMT

Lausanne, July 14, 2011 – Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of innovative therapies, primarily in oncology, has appointed a number of management figures to key positions, which will help ensure the perennial success of the group over the long term.

Although Debiopharm is a private company, it is committed to ensure the same level of financial rigor and corporate governance as companies listed on the stock market. It is for this reason that Debiopharm has created a Strategy Committee, which will adopt recommendations in respect of the overall direction of the group, and a Development Committee, which will be tasked with optimising the development stages of Debiopharm’s products. Dr Kamel Besseghir, who joined Debiopharm in 1995 and has been successfully heading Debiopharm S.A. as CEO since 2006, will chair both committees, starting January 1, 2012.

From that same date he will